SightGlass Vision has announced new clinical data showing that its DOT spectacle lenses for myopia control saved more than 1 D of progression on average after 2 years in Chinese children aged 6 to 10.1*† The findings build on previously reported 12-month Control of Axial Length Treatment by High-Contrast Addition in Young Patients (CATHAY) study data and affirm that DOT lenses that have contrast management deliver strong and consistent efficacy in children, the company said in a press release.
Across the full study population of patients in China aged 6 to 13, the lenses slowed average myopia progression by 0.78 D and average axial length progression by 0.40 mm after 2 years of wear vs the control group.1* The findings of 0.78 D represent a 67% reduction in progression, and 0.40 mm represents a 62% reduction in axial length.1*
The full study population findings were presented by Jennifer Hill in “Control of Myopia Using Contrast Modulation Spectacle Lenses in a Chinese Population: 24-Month Results” at the ARVO 2026 Annual Meeting.
Unlike defocus-based solutions, DOT lenses are specifically designed to reduce retinal contrast signaling through the incorporation of light scattering elements.2 The CATHAY 2-year results supplement the sizable body of clinical research that supports DOT lenses’ contrast management approach for myopia control, the company said.
Additional findings from the full study population showed that 59% of DOT lens wearers had 0.50 D or less myopia progression after 2 years, compared with 19% of children in the control group.1*‡ The differences were statistically significant (P<.0001).1*‡
Building on its 4-year North American Control of Myopia Using Peripheral Diffusion Lenses Efficacy and Safety (CYPRESS) study, SightGlass Vision said the company initiated the CATHAY trial to compare DOT lenses with conventional single vision lenses and to evaluate their continued safety and efficacy in Chinese children across 5 clinical sites in China. A total of 172 myopic children aged 6 to 13 completed the second year of the study.
Other research presented at ARVO 2026 further expanded the understanding of DOT lens performance and wearer experience.
“Pupil Size Effect on Myopia Progression with Contrast Modulation Spectacle Lenses” (Webley et al) found no significant association between pupil size and the rate of myopia progression in children wearing DOT lenses at 12 months. In addition, “Viewing Behavior with Contrast Modulation Spectacle Lenses” (Kollbaum et al) showed that children exhibited similar viewing behavior when wearing both DOT lenses and single vision lenses across a range of daily activities, suggesting good visual performance across the lens, in line with previous studies. OM
*Prescribed DOT lens wear time was 10 hours per day.
†LS mean progression difference of 1.01 D between test and control groups.
‡ For ≤0.50 D, control group = 19%; the differences were significant P<.0001.
References
1. SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n=172, 5 sites in China). Overall study patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional single-vision lenses to evaluate their continued safety and efficacy in Chinese children.
2. Rappon J, Chung C, Young G, et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023;107(11):1709-1715. doi:10.1136/bjo-2021-321005